Skip to main content

Advertisement

Table 3 Cox multivariate regression analysis

From: Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

Time Point Variable HR (95% CI) p-value
4 Weeks (n = 93) ≥30% PSA response at 4 weeks 0.51 (0.29–0.90) 0.021
Alb 0.99 (0.51–1.94) 0.978
Hgb 0.90 (0.73–1.10) 0.306
ALP 1.47 (0.91–2.35) 0.112
PSA 1.13 (0.93–1.37) 0.205
NL Ratio 1.72 (1.13–2.62) 0.012
Prior docetaxel use 0.47 (0.27–0.80) 0.005
8 Weeks (n = 92) ≥30% PSA response at 8 weeks 0.40 (0.24–0.69) 0.001
Alb 1.14 (0.56–2.30) 0.716
Hgb 0.96 (0.80–1.15) 0.645
ALP 1.50 (0.95–2.34) 0.079
PSA 1.30 (1.07–1.58) 0.010
NL Ratio 1.80 (1.20–2.70) 0.005
Prior docetaxel use 0.75 (0.44–1.28) 0.285
12 Weeks (n = 91) ≥30% PSA response at 12 weeks 0.48 (0.27–0.83) 0.009
Alb 0.94 (0.50–1.78) 0.849
Hgb 0.94 (0.78–1.13) 0.499
ALP 1.46 (0.90–2.37) 0.122
PSA 1.19 (1.00–1.44) 0.083
NL Ratio 1.87 (1.22–2.87) 0.004
Prior docetaxel use 0.65 (0.38–1.10) 0.108
  1. Cox multivariate regression analyses presented for a ≥ 30% response at four, eight, and twelve weeks along with the variables incorporated into the analyses. P-values in bold text are statistically significant (p ≤ 0.05)